What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment.
Bronte E, Bronte G, Novo G, Bronte F, Bavetta MG, Lo Re G, Brancatelli G, Bazan V, Natoli C, Novo S, Russo A.
Oncotarget. 2015 Nov 3;6(34):35589-601. doi: 10.18632/oncotarget.5853.
CARDIONCOLOGY.ORG ABSTRACT:
B-RAF inhibitors have been linked to QT prolongation, and as such it is imperative to monitor carefully and know how to recognize the signs.
Two classes of molecules targeting B-RAF have recently been approved by FDA: multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib.
© All rights reserved
image source: https://commons.wikimedia.org/wiki/File:Protein_BRAF_PDB_1uwh.png